Loading
MARS 2 is the trial that overturned decades of surgical practice: removing the lining of the lung did not help patients live longer and left them worse off.
Survival was worse with surgery (HR 1.28, 95% CI 1.02-1.60; median 19.3 vs 24.8 months), with more serious adverse events and poorer quality of life. Extended pleurectomy/decortication is no longer recommended outside trials in most guidelines; MARS 1 had earlier cast doubt on extrapleural pneumonectomy.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
335 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Surgery + chemotherapy | 169 | 19.3 months | 1.28 (1.02 to 1.6) | - | link |
| Chemotherapy alone | 166 | 24.8 months |
Shares Pleura, Pleural mesothelioma, Mesothelioma.
Shares Pleura, Pleural mesothelioma, Mesothelioma.
Shares Pleura, Mesothelioma.
Shares Extended pleurectomy/decortication & radical mesothelioma surgery, Mesothelioma.
Shares Dean A. Fennell, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.